Vectors based on herpes simplex virus type-1 (HSV-1) permit delivery of transgenes of up to 150 kb, while the inverted terminal repeats and Rep of the adeno-associated virus (AAV) can confer site-specific integration into the AAVS1 site, which allows sustained expression of a transgene. In this study, combination of the viral elements in HSV/AAV hybrid vectors has been applied for the infectious transfer of the human lysosomal b-galactosidase (BGAL) gene of 100 kb. Temporary expression and functional activity of b-galactosidase (b-gal) could be detected in human b-gal-deficient patient and glioblastoma (Gli36) cells upon infection with the basic BGAL amplicon vector. Sustained expression of b-gal was achieved in Gli36 cells infected with rep-plus, but not rep-minus, HSV/AAV hybrid vectors. None of five clones isolated after rep-minus hybrid vector infection showed elevated b-gal activity or site-specific integration. In contrast, 80% of the rep-plus clones possessed b-gal activity at least twofold greater than normal levels for up to 4 months of continuous growth, and 33% of the clones exhibited AAVS1-specific integration of the ITR-flanked transgene. One of the rep-plus clones displayed integration of the ITR cassette only at the AAVS1 site, with no sequences outside the cassette detectable and b-gal activity fourfold above normal levels. These data demonstrate AAVS1-specific integration of an entire genomic locus and expression of the transgene from the endogenous promoter mediated by an HSV/AAV hybrid vector.
Introduction
The importance of regulatory mechanisms in the control of human gene expression becomes particularly apparent when considering the relatively small estimated number of protein-coding genes in the human genome (20 000-25 000) and the large diversity of proteins existing in the cell. 1 Since sequencing of the human genome, the focus has turned to aspects such as developmental and tissue-dependent differences in gene expression, alternative generation and processing of messages, and polymorphisms and mutations associated with genetic susceptibilities and diseases. In this context, the libraries of bacterial artificial chromosomes (BAC) containing the entirety of the human genome has become a vital tool. Transduction of cells with a BAC comprising an entire gene locus can enable cell-specific and physiologically regulated gene expression, as well as the full spectrum of isozymic forms of a protein derived from a given locus.
Introduction of BAC-DNA into a cell by conventional chemical or physical methods of transduction is inefficient in most cell types and results in abnormally high levels of expression in the few transduced cells. The iBAC system allows the simple and fast generation of amplicons for efficient viral gene transfer of single genes encoded in genomic BAC-DNA clones into cells using herpes simplex virus type-1 (HSV-1) virions. 2 HSV-1 is a dsDNA virus with a genome of about 150 kb. 3, 4 Amplicons are bacterial plasmids that contain only an origin of replication (ori S ) and a DNA packaging/cleavage signal (pac) (together about 1 kb) from HSV-1, which mediate replication of amplicon DNA and subsequent packaging of the concatenates into HSV virions. [5] [6] [7] [8] Amplicon vectors can incorporate foreign DNA of up to about 150 kb. [9] [10] [11] These vectors are generated with the aid of replication-conditional helper-virus or in a helper virusfree packaging system with titers between 10 7 and 10 11 transducing units/milliliter (tu/ml). 8, [12] [13] [14] DNA delivered by HSV amplicon vectors persists only temporarily in the nucleus of the infected cell. To achieve stability of the transferred amplicon DNA, elements from other viruses have been incorporated into HSV vectors including those from Epstein-Barr virus 9, 15 or adenoassociated virus (AAV). [16] [17] [18] These 'hybrid' vectors can maintain the amplicon DNA in an episomal form or achieve site-specific integration of the transgene into the genome, respectively.
AAV is a helper-dependent virus that replicates in the presence of a helper virus, such as adenovirus (Ad) or HSV-1 and integrates specifically into the AAVS1 site on human chromosome 19q13.3-qter in the absence of the helper. [19] [20] [21] The AAV genome is a linear, single-stranded DNA (4.7 kb) containing two genes, rep and cap, flanked by inverted terminal repeats (ITRs; 145 bp). The rep gene encodes the regulatory proteins Rep68/78 and Rep52/40, expressed from the p5 and p19 promoter, respectively and emanated from alternative splicing. AAV ITRs and Rep68 or Rep78 have been shown to catalyze replication as well as site-specific integration of the ITR-flanked DNA into the genome. [22] [23] [24] [25] Recent experiments have demonstrated that a 138 bp fragment of p5, the integration efficiency element (p5IEE) containing the p5 promoter, can also mediate site-specific integration with a 10-100-fold higher efficiency than the ITRs. 26 HSV/AAV hybrid vectors combine the HSV-1 elements ori S and pac with the AAV ITRs flanking the gene of interest and the rep-gene placed outside the ITR cassette. 27, 28 This design combines the transgene capacity of HSV-1 with the site-specific integration potential of AAV. In several studies using these HSV/AAV hybrid vectors sustained transgene expression was achieved by site-specific integration of the ITR cassette. [16] [17] [18] 29 In one case expression of green fluorescent protein (GFP) encoded in the transgene could be detected in dividing cells for up to 12 months, with GFP sequences integrated into the AAVS1 site and no additional vector sequences detectable in the majority of the 293 clones analyzed. 18 The largest reported insert successfully integrated in the AAVS1 site using an HSV/AAV hybrid vector was 22 kb, but in that case the transgene was not expressed. 16 The aim of the present study was to evaluate the potential for AAVS1-specific integration and expression of an entire gene under control of its endogenous promoter using the HSV/AAV vector. The gene (BGAL) encoding human lysosomal b-galactosidase (b-gal) was considered ideal for this purpose, since it underlies a human hereditary disease and the successful transfer and activity of the enzyme can be monitored in the cell using artificial substrates.
Two phenotypically distinct lysosomal storage disorders, GM 1 gangliosidosis and Morquio B disease, are both caused by the autosomal-recessive deficiency of acid b-gal. 30 Morquio B disease is mainly characterized by connective tissue and skeletal deformities, whereas GM 1 gangliosidosis is primarily a neurovisceral disorder with progressive brain dysfunction and accumulation of GM 1 gangliosides in the central nervous system. The human BGAL gene on chromosome 3 is composed of 16 exons. 31, 32 Two proteins are generated by alternative splicing of the glycosylated 85 kDa precursor, enzymatic active lysosomal acid b-gal, 64 kDa and the elastin binding protein (EBP), 67 kDa. In lysosomes, the b-gal protein forms a complex with protective protein/ cathepsin A (PPCA), a-neuraminidase (NEUR) and N-acetylaminogalacto-6-sulfate-sulfatase (GALNS) and catalyzes the hydrolysis of b-linked galactose residues from glycoproteins, sphingolipids or keratan sulfate. The EBP binds to PPCA and NEUR on the cell surface and is involved in elastic fiber assembly and defects in EBP can cause impaired elastogenesis in fibroblasts from GM 1 gangliosidosis and Morquio B disease patients. 33, 34 These lysosomal storage diseases are an attractive model for gene therapy as recovery of even 1-10% of normal enzyme levels can be sufficient for the reduction of the lysosomal storage material and amelioration of the disease state. 35 In addition, enzyme secreted from transduced cells can be recaptured by non-transduced cells through the mannose 6-phosphate receptor, thus providing a cross-correction mechanism. 36 Furthermore, there are several different animal models available, including knockout mice, which are defective in b-gal activity and have a neurodegenerative phenotype. 37, 38 In this study, the entire human BGAL gene including flanking sequences (133 kb) was inserted into a basic HSV amplicon between the ITR sequences in an HSV/ AAV hybrid amplicon. Transitory recovery of b-gal activity was verified by enzyme assays in GM 1 fibroblasts infected with the HSV BGAL amplicon vector. Furthermore, stable expression of b-gal was achieved in human cells infected with the HSV/AAV amplicon vector, with increased enzyme activity in most of the clones analysed. Additionally, some of these clones also exhibited integration of the BGAL gene into the AAVS1 site. Therefore, HSV/AAV hybrid vectors permit sitespecific integration of an entire gene and enable sustained expression of the transgene.
Results
Construction of HSV and HSV/AAV amplicon vectors containing the entire BGAL gene or BGAL cDNA
The genomic locus containing the human lysosomal BGAL gene was obtained by screening a human genomic BAC library. The BAC-BGAL 48 clone used in these experiments contains the entire BGAL gene, including the 5 0 UTR, SP1-binding sites, transcriptional start site 32 and surrounding genomic sequences ( Figure 1a ). To fit this genomic fragment (160 kb) into HSV virions, 28 kb were deleted from the 5 0 end of the locus (BAC-BGAL 48D28; Figure 1b ). Then this shortened BGAL-BAC was cloned into a standard HSV amplicon to yield pHgBGAL (Figure 1c ) or into an HSV/AAV hybrid amplicon with the AAV rep gene, pAHr-gBGAL ( Figure  1d ), and without it, pAH-gBGAL. All constructs contain the HSV-1 elements ori S and pac, approximately 133 kb of BGAL sequences, including all exons and introns, and additional 16 kb at the 5 0 end and 17 kb at the 3 0 end, as well as a GFP expression cassette under control of the HSV-1 immediate early (IE) 4/5 promoter. In the hybrid vectors the BGAL gene, an additional, non-expressed GFP sequence and a blasticidine resistance gene (BS) are flanked by the AAV ITRs. Furthermore, the pAHrgBGAL amplicon contains the AAV rep-gene coding for all for Rep proteins with its own promoters placed outside the ITR-flanked cassette. In the pHGC-cBGAL amplicon (Figure 1e ), the human BGAL cDNA is under control of the HCMV IE promoter and the GFP is expressed from the HSV-1 IE4/5 promoter.
During viral vector generation, amplicon DNA is replicated as a concatenate and packaged into HSV virions with a capacity of about 150 kb. The three different BGAL gene amplicons have a size of about 150 kb, while the BGAL cDNA amplicon has a size of 9 kb. Therefore, only one copy of the genomic BGAL amplicon, and 17 copies of the pHGC-cBGAL DNA are packaged into one virus particle.
The titers of the concentrated vector stocks were on average 4.4 Â 10 7 tu/ml for the HGC-cBGAL amplicon vector, 3.3 Â 10 7 and 1.0 Â 10 7 tu/ml for H-gBGAL and AH-gBGAL, respectively, the rep-containing hybrid vector, AHr-gBAL, had a lower titer of 2.0 Â 10 6 tu/ml To measure enzyme activity in cells two different tests were performed, X-gal staining and an enzyme assay with 4-MU-gal as substrate. For X-gal staining GM03589t cells were infected with HSV amplicon vectors encoding BGAL, H-gBGAL, the BGAL cDNA, HGC-cBGAL or just GFP, HGCX. Forty-eight hours after infection cells were examined for GFP fluorescence. 
Stable blasticidine-resistant clones from HSV/AAV amplicon vector infected Gli36 cells
Previous studies have shown that HSV-1 amplicon vectors can deliver entire active genes to cells transitorily. 2, [9] [10] [11] The focus of the present study was on stable transduction and expression of the BGAL gene in cells, ideally through integration at the AAVS1 locus.
In initial experiments, b-gal-deficient fibroblasts were infected with rep-minus AH-gbGAL and rep-plus AHrgBGAL hybrid amplicon vectors, replated and subjected to drug selection. However, even after several attempts, it was not possible to isolate single clones for further analysis of b-gal activity and site-specific integration due to the slow growth of these cells. 
Long-term increased b-gal activity in AHr-gBGALinfected cells
To confirm b-gal activity over extended periods of time following transduction with the BGAL gene, enzyme activity was periodically assessed for over 4 months of continuous growth of clones. Fluorometric analyses were performed on naïve Gli36 cells as well as all AH-gBGAL and AHr-gBGAL clones (Figure 4a ). Levels of enzyme activity in the clones, measured between 15 and 18 weeks after infection are indicated as fold increase in comparison to normal enzyme activity in Gli36 cells. Of five clones derived from AH-gBGAL-infected cells none showed an increase of enzyme activity of over twofold (Table 1) . By contrast, of 24 clones from AHr-gBGALinfected cells, 5 possessed values comparable to AH-gBGAL clones, while 12 exhibited enzyme activities between two and fourfold higher and 7 clones greater than fourfold higher than activity in Gli36 cells. Clone number R1/2.2 had the highest activity with approximately 10 times the level of uninfected cells. Although there was some variation in the absolute activity values during the time analysed, the relative tendency of high or low enzyme activity in a given clone in comparison to other clones or Gli36 cells was consistent. As an internal control, activity of b-glucuronidase was measured in parallel in all samples. Here, none of the clones had values of over twofold b-glucuronidase activity compared to naïve Gli36 cells (Figure 4b ). Thus, delivery of the BGAL gene by means of a Rep-expressing HSV/AAV hybrid amplicon vector resulted in elevated enzyme activity (4twofold) in about 80% of clones from infected Gli36 cells.
Specific integration of the ITR-BGAL gene cassette into the AAVS1 site and integration of rep-sequences
Next, the integration mode of the 143 kb ITR-flanked cassette was analyzed. For this, genomic DNA from all AH-gBGAL and AHr-gBGAL clones as well as naïve Gli36 cells were subjected to Southern blot analysis. For wild-type AAV the main proviral structure consists of 2-4 tandem copies of the AAV genome 40, 41 inserted in the AAVS1 site in chromosome 19q13.3-qter. 19, 21, 42 To identify both orientations of potentially integrated ITR cassettes, three different probes were designed (Figure 5a ). One probe is specific for the AAVS1 site (AAVS1), and two (BS and GFP) hybridize to a region between the ITR and a restriction site inside the ITRflanked cassette adjacent to the AAVS1 probe corresponding to both orientations. The blots were hybridized with the AAVS1-specific probe, stripped and then rehybridized with the BS (Figure 5b ) or GFP-specific probe (data not shown; see Table 1 ). In the AAVS1 blots a band of about 5.5 kb was present in all samples analyzed, consistent with the predicted size of the digested AAVS1 locus. AAVS1-specific rearrangements, indicated by additional AAVS1-specific bands, were not visible in any of the AH-gBGAL clones but could be seen in 15 out of 24 AHr-gBGAL clones (Table 1) . Re-hybridization of the same blot with the BS-specific probe showed colocalization of rearranged AAVS1 bands with BSspecific bands in five clones (R1/2.4, R1/2.9, R1/2.11, R1/5I.2 and R1/20.2) (Figure 5b ) and with the GFPspecific probe in three clones (R1/5II.1, R1/20.1 and R1/20.5). This colocalization indicates AAVS1-specific clones. In addition to ITR-mediated integration, efficient site-specific integration can also be mediated by the p5IEE 26,43 present in AHr-gBGAL vectors. Analyses of AAVS1-vector DNA junctions in Ad/AAV vector transduced cells revealed that the break points occurred in the p5IEE. 44 Therefore, clones with p5IEE-mediated integration of AHr-gBGAL DNA should be positive for rep-sequences and have shifted AAVS1 bands in Southern blot analysis.
To identify rep-sequences integrated into the genome, PCR analysis of genomic DNA from all clones and Gli36 cells was performed with rep-specific primers. An 1178 bp rep-fragment could be amplified from 14 of the AHr-gBGAL clones (R1/2.3, R1/2.4, R1/2.6, R1/2.7, R1/ 2.10, R1/5I.1, R1/5I.2, R1/5I.5, R1/5I.6, R1/10.1, R1/ 10.2, R1/10.3, R1/20.1 and R1/20.5; Figure 6 ), but none AH-gBGAL clone or Gli36 cells (Table 1) . Hence, 58% of the AHr-gBGAL clones contained rep-sequences integrated in the genome.
In summary, in the current analysis of 24 clones, infected with the AHr-gBGAL amplicon vector, AAVS1-specific integration of the ITR transgene cassette was verified in 33% of the clones. In addition, some of the clones possessed shifted AAVS1 band(s), integrated repsequences and b-gal activity of at least twofold of normal, suggesting possible p5IEE-mediated site-specific integration of the gene (Table 1) . However, the actual site of integration, whether AAVS1-specific or random, was not determined. Integration of 100 kb gene via HSV/AAV amplicon vector A Oehmig et al Expression of the BGAL gene from the endogenous promoter integrated into the AAVS1 site could only be verified in clones with no random integration. However, site-specific integration of the gene can occur either by means of the ITR cassette or as a part of the amplicon DNA via the p5IEE. Since p5IEE mediated integration of amplicon DNA cannot be unambiguously verified with the current analysis or distinguished from random integration events, the focus was directed towards the eight clones with AAVS1-specific integration of the ITR cassette. In these clones, the detection of rep-sequences and GFP fluorescence would be an indication of random integration or site-specific integration on the other allele, since both the Rep-gene and the GFP expression cassette are located outside the ITR cassette. On the other hand, integration of the entire ITR cassette should lead to the detection of one GFP and one BS-specific signal in Southern blot analysis.
Clone R1/20.2 satisfies all necessary criteria for a single integration event of the ITR cassette at the AAVS1 site. In this case the AAVS1-shifted band colocalized with a BS positive band, cells of this clone did not exhibit green fluorescence and no rep sequences were detectable. The b-gal activity in this clone was about fourfold higher than that in naïve Gli36 cells also supporting integration of the entire BGAL gene and expression from the endogenous promoter at the AAVS1 site with enhanced enzyme activity.
Discussion
The ability to transfer a complete gene to another cell into a defined genomic site has important implications with respect to genetic analysis and provides novel opportunities in the field of gene therapy. Amplicon vectors containing only non-coding elements from HSV-1 can transfer entire genomic loci up to 150 kb 2,9-11 and studies with HSV/AAV vectors have verified sustained expression of the transgenes integrated into the AAVS1 site, so far only with cDNAs under viral promoters. [16] [17] [18] 29 The present study extends this HSV/AAV strategy by demonstrating stable delivery of a 133 kb genomic sequence containing an active BGAL gene. Here, the entire human lysosomal BGAL gene was transferred to cells in culture using an HSV or HSV/AAV hybrid amplicon vector, respectively. The activity of the enzyme could be demonstrated in b-gal-deficient GM 1 fibroblasts, and in addition site-specific integration of the gene and expression from the AAVS1 site by means of the endogenous BGAL promoter could be shown in a human tumor cell line.
The gene encoding the human b-gal enzyme is located on chromosome 3 and spans a region of 462.5 kb. 31, 32 In this work, sequence analysis and pulsed field gel electrophoresis determined the size of the gene to be about 100 kb, from the promoter region to the potential polyadenylation signal. A genomic region of 133 kb Genomic DNA from all Gli36 AH-gBGAL-or AHr-gBGAL clones was digested with EcoRV and Southern blots hybridized with an AAVS1-specific probe, stripped and reprobed with blasticidine-specific sequences. Site-specific integration is indicated by colocalization of the AAVS1 with the BS probe (arrows). Figure 6 PCR analysis for Rep-coding sequences. Genomic DNA from all Gli36 AH-gBGAL-or AHr-gBGAL clones was tested for integrated rep-specific sequences. Naïve Gli36 cells served as negative control. The correspondent PCR fragment of 1178 bp is indicated by the arrow. M, marker, 1 kb ladder.
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with HGC-cBGAL at low MOI was expected to be much higher than that obtained with H-gBGAL. Further, both GFP and the BGAL cDNA are expressed from strong viral, IE promoters, the IE 4/5 promoter from HSV-1 and the IE HCMV promoter/enhancer, respectively, while the BGAL gene is under control of its endogenous promoter. By comparison, in HeLa cells expression levels of a reporter gene from the BGAL promoter was comparable to the expression from the Rous sarcoma virus (RSV) promoter, 32 whereas the RSV promoter has shown to be about 4.7 times weaker than the cytomegalovirus (CMV) promoter. 45 Therefore, 3 days post-infection, the expression of the BGAL gene would be expected to be much weaker than expression of the GFP cassette. In addition, expression from the endogenous BGAL promoter is also dependent on the state of the cell. Even in normal fibroblasts staining could only be seen in a fraction of the population due to the low sensitivity of the assay. Depending on the state of the cell that becomes infected by the virion the gene will potentially not be expressed to a detectable level by X-gal staining. It is also possible that given the large size of the BGAL gene, it underwent rearrangement leading to inactivation during expansion and packaging of the amplicon vectors, such that some virions encoding GFP contained a disrupted, inactive copy of the BGAL gene. The infectability of GM 1 fibroblasts with the H-gBGAL vector and expression levels of the BGAL gene were sufficient to show b-gal activity in cell lysates by fluorometric analysis, due to the higher sensitivity of the measurements at the fluorometer compared to X-gal staining. Although, the detected b-gal activity in H-gBGAL-infected cells appeared lower than the activity measured in normal human fibroblasts, this is due to the fact that only a portion of cells were infected with the vector. If values are normalized to % infected cells, levels are actually somewhat higher in infected GM 1 cells as compared to normal cells.
The gold standard in gene therapy for metabolic disorders is the efficient transfer and sustained, physiologically regulated expression of the transgene of choice. Frequently, this intention is hampered by the loss of the introduced DNA or shutdown of the promoter controlling the expression of the transgene. In this study, the entire genomic locus of the BGAL gene (133 kb) was flanked by AAV ITRs and the entire cassette (143 kb) transferred into cells by means of an HSV/AAV hybrid vector to achieve AAVS1-specific integration and sustained transgene expression from the endogenous promoter. Inclusion of the AAV rep-gene in the hybrid vector, as compared to its absence, had three distinct effects. For one, expression of Rep proteins caused a reduction in viral titer by about five times compared to the non-rep containing hybrid vector. This is in comparison to HSV/AAV hybrid vectors containing about 10 kb as described by Heister et al. 18 where the reduction in titers was much more dramatic (100-1000-fold), perhaps because the smaller size of the amplicon allowed more efficient transfection and higher levels of Rep during packaging which would inhibit replication of amplicon DNA and helper virus genome. A negative effect of Rep on virus replication has been seen with HSV and other HSV/AAV sequences, 17, 18, 29, 46 and even more so with Ad and Ad/AAV sequences. [47] [48] [49] On the other hand, AAV Rep had a positive effect on stable integration frequency. The number of stable blasticidine resistant clones after infection with the rep-plus vector was about 6.5 times higher than with the rep-minus vector. In addition, most of the clones infected with the rep-plus vector had clearly elevated b-gal activity, with the activity of another lysosomal enzyme remaining constant. Virtually, 80% of the clones infected with rep-plus vector had sustained levels of b-gal activity at least two times that of uninfected cells over continuous growth for up to 4 months, the longest time point tested. In comparison, all clones from AH-gBGAL-infected cells exhibited b-gal activity of less than twofold of normal levels. However, since only five clones derived from the rep-minus vector were analysed this data is not sufficient to draw any conclusion about a lower enzyme activity in clones derived from this vector as compared to the rep-plus vector. Possible explanations for these differences in levels of activity among rep-plus derived clones could be relative numbers of integration events of active BGAL transgenes per cell and/or downregulation or upregulation of BGAL expression by adjacent genomic sequences. Of five clones derived from BGAL rep-plus vectorinfected glioma cells with b-gal activity twofold less than normal levels, only one was positive for rep sequences, while 10 out of 12 with 2-4-fold activity and three of seven clones with activity over fourfold of normal displayed a signal-specific for rep by PCR. By this parameter there was no indication that Rep had a negative effect on cell growth or b-gal activity. But Rep is assumed to have an effect directly after infection on replication and integration of AAV sequences. In wt AAV, Rep68/78 causes the rearrangement of the AAVS1 site and replication of the ITR cassette before site-specific integration.
22,50-52 Thus, additional copies of the transgene cassette can be generated and integrated. Further, in AAV vectors, which lack rep sequences, the ITR cassette is often integrated into actively transcribed regions of the genome. 53, 54 Since AH-gBGAL and AHr-gBGAL both contain the AAV-ITR, the difference in b-gal activity is presumably not a consequence of transgene integration into different sites in the genome, but could be caused by the combination of different copy numbers of the BGAL gene and integration into different sites of the genome, with the AAVS1 site presumably supporting higher levels of transgene expression. A similar effect could be seen with Ad/AAV vectors, with a b-globin locus control region (LCR)-CMV-GFP cassette, integrated into the AAVS1 site. In that case, GFP expression from the AAVS1 site was significantly higher than expression from other sites. 55 However, with the experiments conducted in our studies, it was not possible to determine the cause of the different b-gal activities observed.
Unlike in other HSV/AAV hybrid vectors tested to date, only one copy of the BGAL gene within the amplicon DNA can be packaged into an HSV virion. This would include one copy of the blasticidine cassette and two of GFP coding sequences, with the one between the ITRs lacking a promoter (and thus inactive) and the one outside the ITR cassette having a promoter (and being active). Therefore, in Southern blot analysis if only integration of the ITR cassette occurred the clone should be positive for BS and GFP-specific signal of the appropriate restriction fragment size. The integration of the entire amplicon would lead to BS, GFP (with two different sized fragments) and rep signals. Most of the Integration of 100 kb gene via HSV/AAV amplicon vector A Oehmig et al clones do not display this simple pattern of signals but suggest a combination of both, indicating that integrations of part or all of the amplicon occurred, including the ITR-flanked sequence. With the 143 kb ITR-flanked cassette tested in the present study, one-third of the clones showed AAVS1-specific integration of the ITR cassette. But the majority of the clones with a site-specific integrated ITR cassette also exhibited features of unspecific integrated vector sequences, like green fluorescence and/or rep-sequences in the genome. However, in the rep-plus BGAL clones detection of green fluorescence or rep-sequences could also be explained by site-specific integrations mediated by the p5IEE in rep. Additionally, recent analysis with Ad/AAV vector, containing a 27 kb globin-LCR-GFP transgene also revealed recombination of the transgene into the genomic globin LCR site in 25% of the clones. 55 In gene therapy, homologous recombination of an introduced transgene with the endogenous gene can correct a mutation in the gene through replacement with the wild-type sequence. The possibility of homologous recombination between the transduced and the endogenous BGAL sequences was not assessed in this study but will be a crucial point in future studies.
In a comparable analysis with HSV/AAV hybrid vectors and Gli36 cells about 80% of all clones tested showed site-specific integration and 30% of the clones infected with a rep-plus hybrid also showed integration of amplicon backbone sequences. 29 In 293 cells most clones displayed site-specific integration with no sequences besides what was contained within the ITR cassette being retained, although in some clones with random integration vector sequences were also detectable. 18 In tests with mouse embryonic fibroblasts containing the human AAVS1 site, 50% of the clones had sitespecific integration of the transgene cassette but only one clone had no detectable vector sequences. 17 The reason for the apparent lower frequency of site-specific integration in the present study could reflect the larger size of the ITR-flanked cassette. In AAV vectors the number of integrations is proportional to the MOI, and therefore the number of ITR genomes used to infect the cells in the absence of rep sequences is proportional to the number of integration events since no on-site replication occurs. 41, 56, 57 In our case the lower frequency could also reflect the much smaller number of transgene cassettes transferred into the cell, the low levels of Rep protein, as well as less efficient amplification and integration of an ITR cassette of 143 kb by Rep.
In this study, only one clone out of 24 derived from HSV/AAV BGAL rep-plus infected cells had features of exclusive AAVS1-specific integration of the ITR-flanked transgene cassette with one GFP and one BS-specific sequence signal, no expression of GFP and absence of rep. From the fourfold increased b-gal activity the integration of an entire active BGAL gene into the AAVS1 site can be concluded.
In conclusion, HSV/AAV hybrid vectors permit the delivery, site-specific integration and sustained expression of an entire gene under its endogenous promoter. The collection of BAC libraries comprising the entirety of the human genome and the technical possibilities of manipulating DNA with Escherichia coli and the iBAC systems to convert BAC DNA into HSV amplicon vectors permits simple and efficient infectious delivery of any gene of interest (p150 kb), including regulatory elements in a variety of cell lines. This presents a powerful tool for functional studies of polymorphisms or mutations of a given gene but also offers a multitude of possibilities in gene therapy approaches. The transduced genes and their effect in the cell can be studied not only in culture, but potentially also in long-term studies in animal models in vivo. Future developments for the HSV/AAV hybrid will include improvement of the vector to allow more efficient delivery of entire genes into the AAVS1 site through ITR and/or 5pIEE-mediated integration, and also evaluation of possible homologous recombination and correction of genes at the endogenous site in the genome.
Materials and methods

Vector construction
The human lysosomal b-galactosidase gene (BGAL or GLB1) was retrieved from a genomic library (CIT human D BAC library) by screening with BGAL specific PCR fragments (Incyte Genomics, Wilmington, DE, USA). The optimal size of amplicon DNA to be packaged into HSV virions is about 150 kb. To obtain an appropriately sized BGAL clone, part of the genomic DNA was deleted using Phage l Red recombinase-mediated homologous recombination in E. coli. 58 Briefly, BAC-BGAL 48 DNA (containing chloramphenicol resistance gene, Chl r ) was propagated in E. coli DH10B cells (Invitrogen, Carlsbad, CA, USA), transformed with the arabinose-inducible Red recombinase expression plasmid pKD46 (kindly provided by Dr BL Wanner, Department of Biological Sciences, Purdue University, West Lafayette, IN, USA) according to standard procedures (Maniatis) and cultivated on LB plates containing 50 mg/ ml Amp and 17 mg/ml Chl at 301C. An overnight culture of a transformant was diluted in LB medium containing Amp/Chl, agitated at 301C and after 2 h, L-arabinose solution was added to a final concentration of 0.1%. Electrocompetent cells were generated according to standard procedures.
In parallel, a fragment conferring kanamycin resistance (Kan r ) was amplified by PCR from plasmid pACYC177 (NEB) using primers that possessed Kan specific sequences at the 3 0 end and homology to the BGAL genomic sequence to be deleted at the 5 0 end (del28Kan.for:5 0 -ctaaccctctgtgtgactatgagcaagccactctgccttt ctgagtttgtcatagtaagccagtatacactccg and del28Kan.rev:5 0 -tac cacagtttatgtatccacttacccactgaaggacatcttggttgattcagcttttaccc ctgcatctttgagc). The PCR fragment was purified (QIAquick PCR purification kit, Qiagen, Valencia, CA, USA), digested with DpnI (for 24 h with 40 U enzyme) and gelextracted. The competent cells were transformed with 50-100 ng of the PCR fragment, agitated for 2 h at 301C and incubated overnight at 431C on LB plates containing 17 mg/ml Chl and 20 mg/ml Kan. All clones were replated on Chl/Kan and Chl/Kan/Amp replica plates, Integration of 100 kb gene via HSV/AAV amplicon vector A Oehmig et al cultivated at 371C and clones without Amp resistance were further characterized by PFGE and sequencing analysis (BAC-BGAL 48D28).
The conversion of the BAC-BGAL 48D28 DNA into an HSV amplicon was accomplished using the Cre recombinase-mediated system with the tetracycline-inducible Cre recombinase expression plasmid pCTP-T and amplicon pHG (kind gift from Dr Y Saeki, Ohio State University Medical Center), pAH-ITR-BS and pAHr-ITR-BS as described elsewhere.
8 pAH-ITR-BS and pAHr-ITR-BS are derived from plasmids pAHG-ITR-loxP-GFP and pAHG-p5repSV40pA-ITR-loxP-GFP, respectively, by adding a blasticidine resistance gene (BS) inside the ITR cassette between the human cytomegalovirus (HCMV) IE1 promoter (P HCMV ) and the loxP site and GFP coding sequences.
All amplicon constructs contain the HSV-1 elements, ori S and pac, the GFP cDNA under control of the HSV-1 IE 4/5 promoter (P IE4/5 ), an II-protein dependent origin of DNA replication (oriR6Kg), an Amp r gene and a loxP site. In addition, amplicons pAH-ITR-BS and pAHr-ITR-BS contain an AAV-ITR cassette including the loxP site, surrounded by the HCMV IE1 promoter followed by a blasticidine resistance gene on one side and the GFP coding sequence (no promoter) plus a SV40 polyadenylation signal (pA SV40 ) on the other side. Plasmid pAHr-ITR-BS also includes the full AAV rep gene outside the ITR cassette.
All resulting clones (pH-gBGAL, pAH-gBGAL and pAHr-gBGAL) were analyzed by PCR, restriction enzyme analysis, PFGE and sequencing analysis.
Plasmid pHGCX is a standard HSV amplicon that expresses GFP under control of the P IE4/5 promoter with a multiple cloning site flanked by the P HCMV promoter and the bovine growth hormone polyadenylation signal (pA BGH ) (kindly provided by Dr Y Saeki). 59 For the human BGAL cDNA expressing amplicon pHGCcBGAL, plasmid pHGCX was digested with HindIII and XbaI to insert a self-annealing adapter containing the restriction enzyme recognition sites HindIII, AatII, SalI, NsiI and XbaI to create pHGC-HASNX. Then the BGAL cDNA was excised with XbaI and NsiI from pGEM-BGAL (kindly provided by Dr Kunihiko Suzuki, University North Carolina Sch. Med., Chapel Hill, NC, USA) 60 and inserted into pHGC-HASNX, linearized with the NheI and NsiI according to standard procedures.
Cell culture
African green monkey kidney cells that constitutively express the HSV-1 ICP27 protein (Vero2-2) (kindly provided by Dr R Sandri-Goldin, University of California at Irvine), 61 human glioblastoma cells (Gli36) (kindly provided by Dr David Louis, Massachusetts General Hospital) and primary human fibroblasts (HF5) 62 were cultivated in Dulbecco's modified Eagle's medium(Invitrogen) supplemented with 50 U/ml penicillin and 50 mg/ml streptomycin and 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA). Primary human fibroblasts with deficiency in b-gal activity, GM03589 (Coriell Institute, Camden, NJ, USA) were maintained in Eagle's minimum essential medium (Sigma-Aldrich, St Louis, MO, USA) containing 50 U/ml penicillin, 50 mg/ ml streptomycin, 15% FBS and 2 mM L-glutamate (Invitrogen). All cell lines were incubated at 371C and 5% CO 2 in a humidified atmosphere.
To immortalize the primary human HF5 and GM03589 fibroblasts, cells were transduced with the human telomerase gene. The pBABE-puro-hTERT plasmid (kindly provided by Dr R Weinberg, Whitehead Institute for Biomedical Research) was used to generate retrovirus, as described previously. 63 HF5 and GM03589 cells with 75% confluency were infected with 1-2 ml retrovirus stock in a total volume of 3 ml medium containing 0.1% polybrene (8 mg/ml, Sigma, St Louis, MO, USA). Cells were incubated with this mixture at 371C for 10 h and subsequently washed with 1 Â PBS. This process was performed two times in the case of GM03589t cells. In the next step, medium was added to both cultures and, after 48 h at 371C the entire population was selected and further cultivated in medium including 0.7 mg/ml puromycin. The resulting populations were named HF5t and GM03589t.
Packaging of amplicon DNA into HSV-1 virions, titration of vector stocks and infection of cell cultures HSV-1 amplicon vector stocks were prepared as described by Saeki et al. 59 To determine vector titers (tu/ml), Vero2-2 cells were plated and 24 h later infected with different dilutions of the viral stocks. Another 24 h later the number of GFP-positive cells was determined using a fluorescent microscope. Concerning the transduction efficiency, Vero2-2 cells are in-between Gli36 and GM03589t cells. For infection of cell cultures with amplicon vectors cell monolayers were infected overnight with a MOI of 1 (Gli36) or 5 (GM03589t). After 24 h, cells were washed and further cultivated for 3-5 days.
X-gal staining
Cells were washed two times with 1 Â PBS, fixed with 0.2% glutaraldehyde (Sigma-Aldrich, St Louis, MO, USA) in 1 Â PBS for 5 min at 41C washed again and incubated overnight at 371C (protected from light) in X-gal solution, pH 4.3 (2 mM MgCl 2 , 5 mM K 4 Fe(CN) 6 , 5 mM K 3 Fe(CN) 6 in 1 Â PBS) containing 1 mg/ml X-gal (Fisher Scientific, Pittsburgh, PA, USA).
Enzyme assay (4-MU-gal)
Cells were trypsinized, centrifuged for 10 min at 2000 g and washed with 1 Â PBS. The cell pellet was resuspended in 0.1-1.0 ml H 2 O, the suspension frozen and thawed three times and sonicated two times for 15 s at 41C The protein concentration of the samples was determined with the DC protein assay kit (BioRad, Hercules, CA, USA). In addition, dilutions of bovine serum albumin and water were incubated in parallel as protein standard and blank, respectively. The absorbance was measured using a spectrophotometer at 750 nm.
For the analysis of b-gal enzyme activity sample material was mixed with 100 ml NaCl (200 mM in H 2 O), 100 ml 4-methylumbelliferyl-b-D-galactopyranoside (4-MU-gal) (2 mM in sodium citrate -phosphate buffer, 100 mM, pH 4.0) and H 2 O to a final volume of 0.4 ml, shaken at 371C for 1 h and the reaction stopped by adding 3.6 ml glycine buffer (200 mM, pH 10.8). The activity of the human b-glucuronidase in the sample was determined in parallel by incubating 20 ml 4-methylumbelliferyl-b-D-glucuronide (4-MU-glu) (10 mM in sodium-acetate buffer, 100 mM, pH 4.8) with the sample material for 2 h at 371C and the reaction stopped by the Integration of 100 kb gene via HSV/AAV amplicon vector A Oehmig et al addition of 4 ml glycine buffer. 64 The released fluorescent 4-methylumbelliferone was measured with the fluorometer (TD-700 Laboratory Fluorometer, Turner Biosystems, Sunnyvale, CA, USA) at excitation and emission wavelengths of 365 and 450 nm, respectively. 4-methylumbelliferone was used as fluorescence standard. The protein concentration and enzyme activities were determined in duplicate. Statistical significance was determined by Student's t-test, comparing b-gal activity in H-gBGAL and HGC-cBGAL-infected cells, respectively, with cells infected with the HGCX amplicon vector.
PCR analysis
The presence of Rep-coding sequences in stable Gli36 AHr-gBGAL clones was determined by PCR using 0.2 mg genomic DNA and primer pair Rep.for (5 0 -cttcagccaggta catggagc) and Rep.rev (5 0 -ccacattgaccagatcgcagg) to obtain a fragment of 1178 bp. PCR conditions were as follows: 3 min at 941C 40 cycles with 30 s at 941C 30 s at 631C and 60 s at 721C and 721C for 10 min. Genomic DNA of Gli36 AH-gBGAL clones and Gli36 cells were used as control.
Southern analysis
Total genomic DNA was prepared from all blasticidine resistant Gli36 clones as well as naïve Gli36 cells using the Puregene genomic DNA extraction kit (Gentra, Minneapolis, MN, USA). For each sample 5 mg genomic DNA was digested with either EcoRV alone (40 U) or with EcoRV (25 U) and NotI (12.5 U). In addition, pAHrgBGAL and pRIA, containing a human genomic fragment including the entire human AAVS1 locus (kindly provided by Dr R Kotin, NHLBI) 20 were used as controls. The fragments were separated by agarose gel electrophoresis (0.8%), the gel incubated for 10 min with 0.25 M HCl to facilitate the transfer of high-molecular-weight molecules and blotted onto a nylon membrane (HybondN+, Amersham, Piscataway, NJ, USA) by capillary transfer. Labelling of the probes was performed with 0.1 ng of the corresponding DNA and the PCR DIG Probe Synthesis Kit (Roche Applied Science, Indianapolis, IN, USA). For the AAVS1 probe pRIA DNA was amplified with primer DIG-AAVS1.for (5 0 -ggaggatccgctc agagg) and DIG-AAVS1.rev (5 0 -cctgagccagctcccatagctc agtcg) to yield a PCR fragment of 448 bp. DNA pAHr-ITR-BS was used for the synthesis of an BS-specific probe of 565 bp (DIG-BS.for 5 0 -agcctcaggcagcagccaagcttggtatgg and DIG-BS.rev 5 0 -cggcctctgagctattccagaagtagtgagg) and the GFP-specific probe was amplified from pHy-GFPa DNA with primer pair DIG-GFP1 (5 0 -ggatccatcgccacca tggtgagcaagggc) and DIG-GFP2 (5 0 -gtcgcggccgctttacttgta cagctcgtc). 18 The resulting PCR fragment was 746 bp. Hybridization of the membrane and detection of specific DNA fragments was accomplished according to the manual 'Procedures for Nonradioactive Labeling and Detection' (Roche Applied Science) using DIG Easy Hyb buffer, anti-DIG-alkaline phosphatase antibody and CDP-star (Roche Applied Science, Indianapolis, IN, USA), respectively.
The blots were first hybridized with the AAVS1-specific probe and, after stripping, with either the BS-or GFP-specific probe, with exposure to X-ray film for 1 and 4 h. Stripping was performed by incubating the membrane two times for 15 min in 0.2 N NaOH and 0.1% SDS at 371C.
